Search
Search Results
-
The Abundance of KRAS and RAS Gene Mutations in Cancer
Mutant forms of the RAS genes KRAS, NRAS, and HRAS are important and common drivers of cancer. Recently, two independent teams that integrated cancer...
-
Measurement of KRAS-GTPase Activity
Oncogenic mutations in KRAS typically impact the GAP-mediated and intrinsic GTP hydrolysis activity resulting in elevated levels of cellular...
-
Progress in Targeting KRAS Directly
RAS research has entered the world of translational and clinical science. Progress has been based on our appreciation of the role of RAS mutations in...
-
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer
Genomics has greatly improved how patients with cancer are being treated; however, clinical-grade genomic biomarkers for chemotherapies are currently...
-
Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist?
IntroductionThe mitogen-activated protein kinase (MAPK) signalling network aberrations in metastatic colorectal cancer (mCRC) generate intrinsic...
-
Crystallographic Studies of KRAS in Complex with Small Molecules and RAS-Binding Proteins
RAS proteins play a vital role in regulating downstream signaling and essential cellular processes, positioning them as key players in normal...
-
Targeting KRAS in cancer
RAS family variants—most of which involve KRAS —are the most commonly occurring hotspot mutations in human cancers and are associated with a poor...
-
Differential properties of KRAS transversion and transition mutations in non-small cell lung cancer: associations with environmental factors and clinical outcomes
BackgroundKRAS-mutated non-small cell lung cancer (NSCLC) accounts for 23–35% and 13–20% of all NSCLCs in white patients and East Asians,...
-
A Facile Method to Append a Bio-ID Tag to Endogenous Mutant Kras Alleles
KRAS mutations occur in approximately ~50% of colorectal cancers (CRCs) and are associated with poor prognosis and resistance to therapy. While these...
-
The relationships of OSBPL3 expression with KI-67 expression and KRAS mutations in CRC: implications for diagnosis and prognosis
BackgroundOSBPL3 is overexpressed in a variety of malignancies and is closely associated with tumor growth and metastasis. However, its expression...
-
Distribution and prognostic impact of EGFR and KRAS mutations according to histological subtype and tumor invasion status in pTis-3N0M0 lung adenocarcinoma
BackgroundThe prognostic impact of EGFR mutation as major targetable somatic gene variant on lung adenocarcinoma is controversial. KRAS is another...
-
Luminescence-Based Techniques for KRAS Thermal Stability Monitoring
Various biochemical methods have been introduced to detect and characterize KRAS activity and interactions, from which the vast majority is based on...
-
From bench to bedside: current development and emerging trend of KRAS-targeted therapy
Kirsten rat sarcoma 2 viral oncogene homolog ( KRAS ) is the most frequently mutated oncogene in human cancers with mutations predominantly occurring...
-
KRAS and TP53 co-mutation predicts benefit of immune checkpoint blockade in lung adenocarcinoma
BackgroundPredictive biomarkers in use for immunotherapy in advanced non-small cell lung cancer are of limited sensitivity and specificity. We...
-
Overall survival in patients with advanced non-small cell lung cancer with KRAS G12C mutation with or without STK11 and/or KEAP1 mutations in a real-world setting
BackgroundKRAS mutations occur frequently in advanced non-small cell lung cancer (aNSCLC); the G12C mutation is the most prevalent. Alterations in STK11...
-
A novel intranasal peptide vaccine inhibits non-small cell lung cancer with KRAS mutation
KRAS mutations occur commonly in the lung and can lead to the development of non-small cell lung cancer (NSCLC). While the mutated KRAS protein is a...
-
Quality Control of an Isogenic H/N/KRAS-Less Mouse Embryonic Fibroblast Cell Line Panel
Isogenic H/N/KRAS-less mouse embryonic fibroblast (MEF) cell lines have been developed to assist in cell-based assays of RAS inhibitors. The quality...
-
Glimmers of hope for targeting oncogenic KRAS-G12D
KRAS mutations are one of the most common genetic abnormalities in cancer, especially lung, colon, and pancreatic cancers. Strategies targeting the...
-
KRAS is a molecular determinant of platinum responsiveness in glioblastoma
BackgroundKRAS is the undisputed champion of oncogenes, and despite its prominent role in oncogenesis as mutated gene, KRAS mutation appears...
-
KRASG12C inhibition using MRTX1257: a novel radio-sensitizing partner
BackgroundKRAS activating mutations are considered the most frequent oncogenic drivers and are correlated with radio-resistance in multiple cancers...
